Diadema Partners LP Cogent Biosciences, Inc. Call Options Transaction History
Diadema Partners LP
- $391 Billion
- Q3 2025
Call Options
2 transactions
Others Institutions Holding COGT
# of Institutions
215Shares Held
133MCall Options Held
999KPut Options Held
429K-
Deerfield Management Company, L.P. (Series C) New York, NY9.05MShares$304 Million2.42% of portfolio
-
Fairmount Funds Management LLC Philadelphia, PA9MShares$302 Million28.14% of portfolio
-
Kynam Capital Management, LP Princeton, NJ7.89MShares$265 Million9.57% of portfolio
-
Vanguard Group Inc Valley Forge, PA7.76MShares$260 Million0.0% of portfolio
-
Black Rock Inc. New York, NY7.29MShares$244 Million0.0% of portfolio
About Cogent Biosciences, Inc.
- Ticker COGT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 65,758,300
- Market Cap $2.21B
- Description
- Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found ...